Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Yakugaku Zasshi. 2008 Oct;128(10):1499-505.

[Analysis of designer drugs detected in the products purchased in fiscal year 2006].

[Article in Japanese]

Author information

  • 1National Institute of Health Sciences, Tokyo, Japan. nuchiyama@nihs.go.jp

Abstract

Many psychotropic substances are easily available in Japan via the Internet, thus the spread of drug abuse is becoming more serious problem. To avoid drug abuse, 32 substances have been controlled in Japan since April in 2007 by the Pharmaceutical Affairs Law as designated substances (Shitei-Yakubutsu, classified as 11 tryptamines, 11 phenethylamines, 2 piperazines, 6 alkyl nitrites, 1 diterpene and 1 plant). Although the distributions of these drugs have been decreased through this regulation, new designer drugs are still being found. In this study, we detected 7 designer drugs in 15 products, which purchased just before the amendment of the law, by NMR, GC-MS and LC-MS analyses. Three methylone derivertives (1-(3,4-methylenedioxyphenyl-2-(pyrrolidin-1-yl)-1-pentanone: MDPV, 2-methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one: bk-MBDB, 2-ethylamino-1-(3,4-methylenedioxyphenyl)propan-1-one): bk-MDEA, a MDMA derivative (N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane: N-OH MDMA), a methamphetamine derivative (N-methyl-1-(4-fluorophenyl)propan-2-amine: N-Me-4-FMP), a tryptamine derivative (5-methoxy-N-ethyl-N-isopropyltryptamine: 5-MeO-EIPT) and indan-2-amine were detected. 5-MeO-EIPT was newly identified in this study.

PMID:
18827471
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for J-STAGE, Japan Science and Technology Information Aggregator, Electronic
    Loading ...
    Write to the Help Desk